---
title: "Viatris Q2 earnings on deck: What to expect"
description: "Pharmaceutical company Viatris (NASDAQ:VTRS) is set to announce its Q2 earnings on Thursday, with Wall Street expecting an EPS of $0.56, a 19% decline, and revenue of $3.46 billion, down 9%. Viatris h"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251864780.md"
published_at: "2025-08-06T14:32:46.000Z"
---

# Viatris Q2 earnings on deck: What to expect

> Pharmaceutical company Viatris (NASDAQ:VTRS) is set to announce its Q2 earnings on Thursday, with Wall Street expecting an EPS of $0.56, a 19% decline, and revenue of $3.46 billion, down 9%. Viatris has beaten EPS and revenue estimates 75% of the time over the past year. The stock has dropped nearly 29% this year, attributed to pipeline setbacks and failed R&D efforts, leading analysts to rate it as a Hold. Recent revisions show mixed changes in EPS and revenue estimates.

Pharmaceutical company Viatris (NASDAQ:VTRS) is set to announce its second quarter earnings result on Thursday, before the opening bell. Wall Street expects the Pennsylvania-based drugmaker to post EPS of $0.56, implying a fall of nearly 19% while revenue is expected to decline about 9% to $3.46 billion during the quarter. Over the last one year, V...

### Related Stocks

- [VTRS.US - Viatris](https://longbridge.com/en/quote/VTRS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 市场对晖致公司目前的情绪如何？ | Viatris Inc 的空头头寸增加了 12.02%，目前有 2626 万股被卖空，占可用股份的 2.61%。交易者需要 3.5 天来平仓这些头寸。空头头寸的上升表明市场情绪偏向看跌。然而，与同行相比，Viatris 的空头头寸较少，同行 | [Link](https://longbridge.com/en/news/270733862.md) |
| 晖致公司任命 Lara Ramsburg 为首席人力资源与企业事务官 \| VTRS 股票新闻 | Viatris Inc. 任命 Lara Ramsburg 为首席人事与企业事务官，此职位旨在提升公司的文化和利益相关者沟通。Ramsburg 拥有超过 25 年的经验，曾在 Viatris 和 Mylan 担任多个高管职位，自 2019  | [Link](https://longbridge.com/en/news/271946525.md) |
| 美国食品药品监督管理局（FDA）批准了晖致的 Sandostatin LAR Depot 仿制药版本 | FDA 已批准 Viatris 的 Sandostatin LAR Depot 的仿制药版本。FDA 还接受了 Viatris 针对低剂量雌激素每周贴片的新的药物申请，该贴片用于避孕，目标行动日期为 2026 年 7 月 30 日。此外，F | [Link](https://longbridge.com/en/news/270153300.md) |
| 晖致称 FDA 已批准奥曲肽乙酸盐，并允许 MR-146 进入临床试验阶段 | Viatris 宣布获得 FDA 批准奥曲肽乙酸酯，这是 Sandostatin LAR Depot 的仿制药，用于治疗肢端肥大症和某些肿瘤。FDA 还批准了 MR-146 进行神经营养性角膜病的临床试验。Viatris 计划在 2026  | [Link](https://longbridge.com/en/news/270166060.md) |
| 晖致任命 Matthew J. Maletta 为新任首席法律官 | Viatris Inc. 宣布任命 Matthew J. Maletta 为新的首席法律官，任命将于 2026 年 2 月 9 日生效。现任首席法律官 Brian Roman 将在 2026 年 4 月 1 日的过渡期后离开公司 | [Link](https://longbridge.com/en/news/274665044.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.